Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Stomach Neoplasms 1Nasopharyngeal Carcinoma 1Leukemia, Myeloid, Acute 1Esophageal Neoplasms 1Differentiated Thyroid Cancer 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 4Cisplatin 4nedaplatin 2Heavy Ion Radiotherapy 2Gemcitabine 2donafenib 1apatinib 1Varenicline 1Valganciclovir 1Therapeutics 1Tegafur 1S 1 (combination) 1Platinum 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Nicotine Replacement Therapy 1Mitomycin 1Ifosfamide 1Fluorouracil 1Eucalyptus Oil 1Epirubicin 1Doxorubicin 1Coal Tar 1Chemotherapy, Adjuvant 1Cetuximab 1Carboplatin 1Bupropion 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Nasopharyngeal Carcinoma × donafenib × Clear all
NCT02698111 2023-05-08

Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 1/2 Terminated
20 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡